This finding is somewhat dismissed as a technical issue but, in reality, represents a 27% reduction. Could this be due to changes in the product since the data were first reported or the product first used (perhaps changes in batches of active component, for example, see Quarta [17] or other issues)? Whatever the cause, this significant difference is a product inconsistency that warranted further comment, representing an important aspect of the work to the clinicians -consistent product gives consistent clinical results.
Data comparing the characteristics of the various BoNT-A products and misleadingly comparing these to labeled units are not helping clinicians select products for use. Instead, detailed overall data, notably on history of product consistency, such as those previously published for Dysport Ò , [10] are important for clinicians and these are still awaited for the other BoNT-A products. Perhaps the time has also come to stop discussing BoNT-A complex 'sizes' in a clinical context unless and until data are produced that clearly demonstrate any relevance to clinical use? None now seem likely. Author's Reply
Andy Pickett
The main focus of the letter to the editor by Dr Pickett [1] is the interchangeability of botulinum toxin A dosages between products, and therefore this answer will address this issue.
In contrast to the argument of Dr Pickett, it is justified to draw conclusions on botulinum toxin A products based on the potency. It is true that the units of each product are determined by dif-ferent LD 50 (median dose that is lethal to 50% of animals tested) assays. However, it had been shown that the potency assay carried out by Merz resulted in the same number of units for Botox Ò /Vistabel Ò as for Xeomin Ò /Bocouture Ò . More importantly, it was demonstrated in several clinical studies for neurologic indication [2, 3] as well as in the aesthetic field [4, 5] that Botox Ò / Vistabel Ò and Xeomin Ò /Bocouture Ò are equipotent. This fact is acknowledged in the summary of product characteristics of Bocouture Ò . [6] It is therefore justified to calculate a specific neurotoxin potency based on the potency in each vial, clearly demonstrating that Xeomin Ò /Bocouture Ò requires the lowest amount of clostridial protein to achieve the same therapeutic effect. The reported reduced value for the protein content in the Xeomin Ò /Bocouture Ò vial has been explained in the article [7] and is attributed to the increased sensitivity and precision of the ELISA method used compared with older methods used in the past.
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